WO1981000356A1 - Applicateurs de polymeres medicamenteux - Google Patents

Applicateurs de polymeres medicamenteux Download PDF

Info

Publication number
WO1981000356A1
WO1981000356A1 PCT/US1980/001030 US8001030W WO8100356A1 WO 1981000356 A1 WO1981000356 A1 WO 1981000356A1 US 8001030 W US8001030 W US 8001030W WO 8100356 A1 WO8100356 A1 WO 8100356A1
Authority
WO
WIPO (PCT)
Prior art keywords
applicator
polymeric foam
foam element
core member
polymeric
Prior art date
Application number
PCT/US1980/001030
Other languages
English (en)
Inventor
R Strickman
M Strickman
E Fournier
Original Assignee
R Strickman
M Strickman
E Fournier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Strickman, M Strickman, E Fournier filed Critical R Strickman
Priority to AU63328/80A priority Critical patent/AU6332880A/en
Priority to BR8008784A priority patent/BR8008784A/pt
Publication of WO1981000356A1 publication Critical patent/WO1981000356A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/20—Tampons, e.g. catamenial tampons; Accessories therefor
    • A61F13/2051—Tampons, e.g. catamenial tampons; Accessories therefor characterised by the material or the structure of the inner absorbing core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/08—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of suppositories or sticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Definitions

  • Topical applicators of a porous cellular nature which are primarily designed to be used on the mucous membranes of human or animal body cavities such as the vaginal tract.
  • the invention has particular application to low cost, mass volume, disposable devices pre-impregnated with dry, liquid or semi-liquid therapeutic compositions (102).
  • This invention is directed toward porous cellular topical applicators and more particularly toward the production of such applicators which are smooth- skinned, pre- impregnated and mounted onto a support member in a single operation at considerable savings in production cost and capital investment.
  • 3,228,398 embodies a cylindrical polyurethane foam sponge applicator secured to an elongated rigid stem by means of a combination of a surgical tape substrate and coatings of glue.
  • Elias discloses a smooth-surfaced, topical spongy material for vaginal insertion made of reticulated polyurethane foam with a maximum cell size of 1.5 mm.
  • Another type of applicator disclosed by Fournier in U.S. Patent No. 3,818,911 consists of a pre-moistened vaginal swab machined from cured polymeric foam and shaped in the form of inverted cup-like convolutious for effective removal of debris.
  • reticulated (i.e. open cell) polyurethane foam suffer from a number of physical shortcomings and severe cost disadvantages over the present technology.
  • One such physical shortcoming is caused by the resulting reticulated surface of the machined body of polyurethane foam.
  • the opened cells of such applicators present surface discontinuities which, upon repeated use, can cause friction and irritation on the delicate tissue of the mucous membranes.
  • the present technology allows the body of the foam applicator to be covered by a highly porous but continuous skin surface whose smoothness is very close to the human skin.
  • applicators of this type may require as many as ten manufacturing steps involving a substantial amount of equipment and labor.
  • the present technology allows the production of a similar article, smooth-skinned, pre-impregnated and mounted onto a support member in one single operation at considerable savings in production cost and capital investment.
  • medicaments such as bactericides, germicides, antibiotics and the like
  • Figure 1 is a front elevational view partly in cross section and partly in phantom of a polymeric applicator constructed in accordance with the principles of the present invention
  • Figure 2 is a side elevational view of the device shown in Figure 1;
  • Figure 3 is a cross-sectional view taken through the line 3-3 of Figure 1;
  • Figure 4 is an elevational view of a modified form of the invention.
  • Figure 5 is a cross-sectional view of the device shown in Figure 4;
  • Figure 6 is a cross-sectional view taken through the line 6-6 of Figure 4;
  • Figure 7 is a front elevational view of another embodiment of the invention showing the handle in its folded position for packaging;
  • Figure 8 is a cross-sectional view of the device of Figure 7;
  • Figure 9 is a cross-sectional view taken through the line 9-9 of Figure 7;
  • Figure 10 is an elevational view shown partly in cross section of an even further embodiment of the invention.
  • Figure 11 is a bottom plan view of the device shown in Figure 10;
  • FIGS 12, 13 and 14 are elevational views, partly in cross section, of still further embodiments of the invention.
  • Figure 15 is a front cross-sectional view of an additional embodiment of the invention.
  • Figure 16 is a cross-sectional view taken through the line 16-16 of Figure 15;
  • Figure 17 is an elevational view of a medicated applicator in the form of a therapeutic tampon constructed in accordance with the principles of the present invention.
  • Figure 18 is a bottom view of the device shown in Figure 17;
  • Figure 19 is a cross-sectional view of the device shown in Figure 17 and further demonstrating the use of an inserter;
  • Figure 20 is a cross-sectional view of a modified form of the device shown in Figure 17;
  • Figure 21 is an elevational view of an applicator in the form of a disposable douching assembly and shown in its assembled state;
  • Figure 22 is a cross-sectional view of the device shown in Figure 21 in its packaged condition before assembly;
  • Figure 23 is an elevational view of a medicated sheath which may be used in conjunction with the device of Figure 21;
  • Figure 24 is an elevational view, partially broken away, of the device of Figure 21 in combination with a medicated sheath;
  • Figure 25 is a cross-sectional view taken through the line 25-25 of Figure 24;
  • Figure 26 is a cross-sectional view of a disposable douching sleeve
  • Figure 27 is a bottom view of the sleeve shown in Figure 26;
  • Figure 28 is a modified form of the douching sleeve shown in Figure 26 and further shown in combination with a douching support;
  • Figure 29 is a cross-sectional view of the device shown in Figure 28, and
  • Figure 30 is a cross-sectional view of a mold cavity illustrating the manner in which the various applicators of the present invention may be manufactured. Best Mode for Carrying Out the Invention
  • the various polymeric medicated applicators of the present invention can be classified into three structural groups:
  • this type of digital applicator is comprised essentially of two components: a unitary handle-stem structure 10 and 11 equipped toward its mid-section with an optional safety flange 13.
  • Flange 13 provides support for a pre impregnated polyurethane foam-applicating surface 12 of generally cylindrical shape.
  • the swab portion 12 of the applicator can incorporate a thin, pliable shell 34 (Figure 15) of absorbable medications either meltable to internal body heat and/or miscible on contact with body fluids. While the swab head is seen to range from two to five inches in length, its diameter should preferably not exceed one inch for human use.
  • the handle-stem element 10 and 11 can either have a flat or round cross section and it can be made of either plastic, wood or of some paper composition such as twisted kraft, cardboard or plastic reinforced paper. If made of plastic, the structure can either be injection-molded or extruded from such resins as polyethylene, polypropylene, polyester, polyimide or polyphenylene oxide.
  • the handle portion 10 can be made rigid and aligned straight with the stem 11 as shown in Figure 12 or angled at 10 to 15 degrees from the normal for self-use convenience ( Figures 1 and 2). Or, still further, the handle can be made both flexible and foldable alongside the body of the swab as shown in Figures 6 and 9. These and other design variances will be described in fuller details below along with the description of specific applicators. Irrespective of the material used, the stem portion 11 of the structure must incorporate two important physical features essential to the proper functioning of the product. First, if must have foam adhering surface characteristics and it must have a safety tip-searching head combination.
  • the manufacturing principle of the present applicator involves a two-cavity mold 300 into which the handle-stem element 10 and 11 is secured in a vertical position and around which the uniform reacting mixture is poured. (See Figure 30) Upon curing, the foam solidifies around the stem 11 and takes the shape of the cavity which opens laterally to release the swab assembly. But for the foam to adhere properly to the plastic stem, grippable surface discontinuities of various kinds and preferably perforations through the stem must be provided to eliminate the need for substrate material or for some adhesive requiring additional manufacturing steps.
  • holes 14 incorporated through the foam-supporting structure 11 are particularly desirable as they provide channels for the foamable polymer to flow through during the pouring operation and to solidify into transversal pins or rungs 15 linking both sides of the swab element 12 through the stem portion 11.
  • grippable surface discontinuities could take the form of circular grooves 16, annular ridges 17 or notches 18 as shown in Figures 1 and 2, or any number of variations thereof such as lugs or threads (not shown).
  • the paper-composition stems 11a of Figures 10 and 12 incorporate on their surfaces dimples 19 or knurls 20.
  • the stem-support element of Figures 5 and 8 could be in the form of an extruded and flexible hollow straw 11b whose bellows-like surface discontinuities 24 provide an appropriate grip for the foam sheath to adhere to and to act as a handle.
  • the second important design aspect of the device lies in a combination safety tip and searching head surmounting the distal end of the stem 11 for the dual purpose of preventing internal injury and to help facilitate passage through sphincter muscles.
  • the integral end-portion 21 of such flat support stems are rounded or bulbous shaped and are positioned relatively close to the outer edge of the swab to prevent the foam from "bunching out" at the point of insertion.
  • injection molded tips can be shaped in the form of a flared cup 22 shown in Figure 13, while other rod-like support structures such as those of Figures 5, 8, 10 and 12 are separately fitted with a round or semi-spherical tip 23 of rubber or soft plastic.
  • the particular polymer technology of the present invention allows the foam head to be made in virtually any shape and with a highly permeable skin for liquid absorption or diffusion.
  • the configuration and surface characteristics of the swab can therefore be "tailored" to the specific requirements of any therapeutic application, particularly those of an internal nature.
  • swabs primarily designed to scoop out debris or undesirable secretions are shown in Figures 4 through 9.
  • the swab element of Figures 4 and 5 is comprised of a cylindrically shaped body 12 of uniform diameter with a rounded or oviform top for easy insertion into body or animal cavities.
  • Mechanical scrubbing is accomplished by means of a plurality of semi-circular annular grooves 25 regularly spaced along the length of the swab and into which debris can accumulate for removal.
  • the scooping action is enhanced further by having a similar series of annular troughs 25a separated by concave sections 26 terminating in soft, pliable fins 27.
  • the pliable fins 27 are designed to penetrate into the folds of the canal and to exert thereon a gentle scraping action in both directions scooping debris into the troughs 25a.
  • the safety flange 13a is made of foam and is integral with the swab element 12.
  • the handle section 10a is also covered by a sheath 10b of the same foam so that the swab element 12, flange 13a and their handle form a unitary foam construction around the central supporting structure. Due to the inherent flexibility of the straw and foam composition of the handle 10a, it can be conveniently folded upwardly at 180 degrees as shown in Figures 8 and 9. For packaging convenience, the handle element 10a can be snapped folded and held into a compliant and cooperating open cavity 28 provided on the side of the flange 13a as shown in Figures 6, 7, 8 and 9.
  • Swab configurations shown in Figures 10 and 12 are designed for situations where a softer scrubbing action is indicated.
  • the cylindrical foam applicator 12 incorporates a series of annular V-shaped recesses 25b forming la.teral notches 31 whose depth can range from two to five millimeters depending upon the desired effect.
  • the frequency of these annular recesses can also vary from two to four per inch depending upon the desired degree of mechanical cleansing.
  • the scraping edges can also be gently contoured to reduce friction.
  • the swab element 12 consists of a series of superposed, truncated triangular sections 29 with a rounded base forming a series of slanted scales 31a whose depth and frequency can be made to vary as desired.
  • the foam swab is made to assume a smoother and/or shallower profile as shown in Figures 13 through 16.
  • the swab is made up of a series of superposed concave sections 30 creating at their points of junction a corresponding series of conical scraping edges 31b.
  • the flange arrangement differs somewhat from the previous applicators in that it is comprised of two superposed flange thicknesses: a flat flange support 13c integral with the plastic molded handle 10 and a foam flange 13a integral with the swab element 12.
  • the swab is composed of a series of alternating convex and concave sections 32a and 32b eliminating the formation of scraping edges.
  • This embodiment shows still another variance of the safety flange.
  • the plastic handle 10 incorporates a circular trough 13d in the order of one and a half inches in diameter housing a foam base 13a integral with the swab element 12.
  • the body of the generally cylindrical swab 12 is composed of a series of truncated spheres 33 superposed on top of each other and forming one integral body of foam secured to the stem 11.
  • the applicator incorporates a circular and concave safety flange of a still different structure yet similar in concept to the one shown in Figure 14.
  • the foam flange 13e is encased in a pre-formed trough 13f of thermoformable plastic such as vinyl, polyethylene, latex or even coated paper.
  • the base of foam flange 13a in Figures 10 and 12 could be sprayed after molding with some water-proof compound including such materials as latex, neoprene, natural rubber, waxes or the like.
  • the foam composition of the swab 12 is different from the foam composition of the flange element 13e and each foam element, even though molded separately, can be cast in sequence in the same mold.
  • the applicator shown in Figures 15 and 16 also differs from the previously described devices in that it includes a medicated shell 34 surrounding the foam swab 12. This applicator is preferably manufactured in the following manner.
  • Step 1 The pre-formed flange 13f and medicated shell inserts 34 (not shown) are positioned into the open mold as shown in Figure 30. While the flange inserts are pre-formed preferably from thermoformable materials, the medicated shell 34 can be made in several ways: a) its ingredients can be pre-cast into a smooth, pliable cylinder and inserted into the closed cavity; b) the ingredients can be hot-sprayed onto the open surfaces 301d and 301b of the cavity; c) the ingredients can be brush-coated thereon; d) or a flat sheet of ingredients can be press-fitted into each half of the open cavities. Step 2. The handle-stem element 10 and 11 is inserted vertically into the closed cavity and locked in at the proper level.
  • Step 3 Foam #1 mix comprised of liquid resins and medications added prior to foaming is poured into the closed cavity.
  • Step 4 The foam is allowed to rise and to jell into swab element 12. If a pre-cast cylindrical shell 34 of medications is used, the internal pressure exerted by the rising foam will force the sides of the cylinder against the walls of the cavity, thereby shaping it into the same configuration as the swab element. Irrespective of the way the shell ingredients are applied to the cavity, they will intimately adhere to the surface of the swab.
  • Step 5 A highly hydrophilic foam mix #2 is then poured into flange cavity 13f. Step 6. The foam is allowed to rise and to jell into solid flange 13e.
  • Step 7 Cavities may be opened to release the swab assembly with its medicated shell.
  • the foregoing methodology also applies in part or in whole to the therapeutic tampon of Figures 19 and 20 and to the douching sleeve of Figure 26.
  • the shell coating could be alternately applied to the foam element by dipping it into a bath after molding.
  • more than one shell 34 could be employed and that each shell layer could be comprised of the same or different medication and having the same or different solubility characteristics.
  • the therapeutic tampon is comprised of a series of superposed truncated spheres 102 forming one integral body of foam 101 of generally cylindrical shape. While some degree of surface discontinuity is desirable from the standpoint of anatomical conformity, the tampon element 101 could assume a perfectly smooth cylindrical shape without affecting the drug release properties of the foam.
  • the base of the applicator 101 is comprised of two or more rings 103 of foam substantially larger in diameter than the body of the tampon. Rings 103 are designed to exert pressure against the vestibule of the vaginal canal and to act like the gaskets of a plug to prevent by-pass of the melted medicaments.
  • the external surface of these rings is sheathed with a pre-formed layer 104 of flexible, water-proof material such as vinyl, latex, wax or polyethylene.
  • a pre-formed layer 104 of flexible, water-proof material such as vinyl, latex, wax or polyethylene.
  • the base of the tampon could be dip-coated or spray-coated with similar leak-proof compounds.
  • Insertion and retrieval of the tampon can be accomplished in two different ways depending upon the internal construction of the device.
  • one embodiment is comprised of a central tubular core 105 of semi-rigid material made from polyurethane, nylon, latex or paper-coated laminates.
  • the tubular core 105 extends almost through the entire length of the tampon and incorporates an axial, internal bore 106 of substantially the same length.
  • the diameter of the bore 106 is in the order of five to seven millimeters and allows the rod-like plunger 107 of a reusable inserter 110 to be introduced therein to position the tampon into the vaginal cavity. Once the tampon is in place, the plunger 107 is slid out and removed.
  • a flange 109 integral with the inserter 110, is designed to push up the tampon from the base of its semi-rigid core 105 while the plunger 107 exerts a simultaneous push from the upper portion of the tampon. Since both elements are displacing the tampon at the same rate, perforation from the plunger is made impossible by the position of the flange against the base of the axial core 105.
  • the uppermost portion of the tubular core 105 incorporates an extension of solid material 108 as reinforcement against the tip of the plunger.
  • This type of therapeutic tampon comes equipped with a set of recall strings 111 tied around the base of the tampon just above the neck of the enlarged leak-proof rings 103 as shown in Figure 17.
  • These recall strings 111 are used to withdraw the device similar to any commercial type of catamenial tampon.
  • the recall strings 111 can be incorporated in the mold for the polymeric material of the core 105 and allowed to extend from the base of the tampon.
  • Another embodiment shown in Figure 20 incorporates a solid, axial and rod-like core 112 of semi-rigid, non-breakable material extending substantially through the entire length of the body of foam 101. While the generally cylindrical foam portion of the tampon can assume any number of surface features, the core element 112 should preferably be made of polyurethane, elastomer, nylon, latex, polypropylene, or combinations thereof.
  • the bottom section of the tampon incorporates a semi-spherical cavity 113 through which protrudes the tail-end of the core element 112 shaped in the form of an integral loop 114. While the user can grasp through the open cavity 113 the lowermost section of the polymeric core 112 and utilize it as means of inserting the tampon, the recall loop 114 serves the purpose of withdrawing the device.
  • the basic concept of the topical foam swab as a carrier and applicator of water-active drugs has been expanded further to a douching swab implement with or without a soluble sheath of medications as generally shown in Figures 21 through 25.
  • the drug carrier could be a disposable sleeve of medicated polyurethane foam slideable over a douching tip shown in Figures 26 through 29.
  • the douching swab assembly comprises a body of highly porous foam 201 centered over a plastic douching tip 202 incorporating a plurality of exit holes 205 for the douching liquid.
  • a series of annular knurls 203 and saw-tooth fittings 204 are incorporated into the tip.
  • the douching tip 202 is connected through a flared neck 206 to a reversible screw cap 207.
  • a reversible screw cap allows the douching swab element 201 to be screwed upside down into the empty douching container 208 and is sealed on its opposite open side by means of a peel-off strip of foil 209.
  • the douching container could be either a squeeze-type blow-molded bottle or a collapsible bladder of plastic film or laminate .
  • the foil 209 is removed and the douching swab is inverted and screwed onto the top of its container 208 which has been previously filled with water. (See Figure 21)
  • the water oozes out through the swab along with the medicaments.
  • These medicaments can be admixed to the water in powdered or liquid concentrate form. Alternately, they can be pre-impregnated into the douching swab foam 201 or incorporated as a soluble shell to the surface of the swab.
  • small perforations 211 can be provided over its surface so that both internal and external sides of the sheath can be subjected to water contact from the douching nozzle.
  • a more economical alternative to the foregoing douching embodiment is comprised of a disposable sleeve of porous foam 212 incorporating a thin outer shell 213 of soluble medications and slideable over a reusable plastic douching tip 214.
  • the body of the foam sleeve 212 can incorporate any number of surface features, such as superposed concave sections 215. While the liquid forced through the holes 205 of the douching tip 214 will ooze out through the sleeve along with the medicaments, these medicaments can also be diffused either from the pre-impregnated foam sleeve 212 or from the soluble shell 213 which can be incorporated to any desired extent over the surface of the applicator. More specifically, the shell can cover the entire applicator as shown in Figure 19, or only a part thereof such as shown in Figure 26.
  • the foregoing douching swab embodiments are therefore capable of achieving a triple therapeutic action, hydraulic, mechanical and medicinal, which is deemed to be most beneficial for a substantial number of vaginal disorders.
  • the unique characteristics of the polyurethane technology of the present invention are applicable to a variety of medicated applicators for body cavities. These applicators differ markedly from the prior art from the combined standpoints of internal structure, polymeric composition, release of pre-impregnated medications and manufacturing method.
  • the core of the technology and of its present product applications resides in the. ability of producing a generally cylindrical body of foam or tubular swab element capable of incorporating at least nine distinct features:
  • the polymeric swab element can be integrally and permanently bonded to a variety of internal supporting structures during the molding operation which obviates the need for substrates, primers, adhesives or any other external devices.
  • the polyurethane swab is inherently covered with an extremely smooth, thin and pliable skin which is highly porous to the absorption of body fluids and/or to the diffusion of liquid medications.
  • the polyurethane foam is highly hydrophilic and is capable of absorbing up to 25 times its own weight of liquids.
  • the polymeric swab can be cast in a mold into virtually any shape over any kind of support which eliminates a large number of costly and time consuming manufacturing steps.
  • the foam swab can be pre-impregnated by as much as 60 percent by weight with almost any desired combinations of chemicals and/or medications activatable by internal body heat, water contact or body fluids.
  • the swab element can be intimately coated with a solid or semi-solid shell of absorbable medications either meltable to internal body heat and/or miscible on contact with body fluids.
  • the shell can be comprised of several thin layers of identical medications releasable over a period of time while the swab carrier can be pre-impregnated with a different medication for secondary treatment of diseased mucous or skin surfaces.
  • the various chemicals and medications admixed to the foam can be encapsulated for controlled release action.
  • the medications diffused from the foam can be made to effervesce for better penetration into the crypts and folds of certain body cavities.
  • the foam swab can be adapted to an equal variety of products for specific medicinal treatments.
  • the foam swab can be used as a "swabstick" for medical, surgical or veterinary applications.
  • the foam element can be turned into a douching swab for routine or therapeutic feminine hygiene as illustrated in Figures 21-29.
  • the foregoing internal and external physical characteristics of the foam swab result from the structural arrangement of the cellular matrix which is composed of collapsed, ruptured, stretched, distorted, reticulated and swollen cells as well as normal cells. Randomly, interspersed throughout the cellular structure are fibrous threads or filaments caused by a particular over-stirring of the foamable polymers which increase the structural strength and resiliency of the foam.
  • the cellular material of the present invention which has a densely structured cellular matrix of 6 to 30 lbs. /ft. 3 is easily wetted and readily discharges the pre-impregnated additives upon gentle pressure or even upon weak internal muscular action.
  • the preparatory procedure found most suitable utilizes a first mixing operation to obtain a partially polymerized mass and one or more additional mixing operations to regulate the consistency and viscosity of the polymeric mass during which medicaments or other additives are dispersed therein. It is essential, however, that the first mixing step be performed in the absence of additives which interfere with the foam-making reactions.
  • prepolymer urethane resin is admixed and reacted with a catalyst at 500 to 2500 RPM for 30 to 100 seconds to produce the partially reacted polymeric mass.
  • the prepolymer resin may be prepared from polypropylene glycol and toluene diisocyanate according to known technology or they may be purchased commercially.
  • the prepolymer resin to be used in the production of the foam swabs should have the following characteristics: a Brookfield viscosity at 25oC between 5000 and 15,000 CPS, preferably between 7200 and 9400 CPS; an isocyanate content (NCO) between 6 and 12 percent; a hydroxyl number ranging from 40 to 80 but preferably between 50 and 60 and a molecular weight of the polyol component ranging between 1800 and 4000.
  • NCO isocyanate content
  • a hydroxyl number ranging from 40 to 80 but preferably between 50 and 60
  • a molecular weight of the polyol component ranging between 1800 and 4000.
  • two types of commercially available prepolymer resins may be used in the above procedure.
  • the first type such as polyether prepolymer F-202 manufactured by Stepan Chemical Company requires the addition of 1.5 to 5.0 percent by weight of a catalyst consisting by weight analysis of 18 to 22 percent triethanolamine, 10 to 15 percent triethylenediamine and 60 to 70 percent water.
  • the second type is preformulated by the manufacturer in a manner that requires the addition of water only to start the reaction and to obtain a foamable mass.
  • Example of such prepolymer resins are HYPOL 2001 and 3001 manufactured by W. R. Grace Chemicals which require, according to the manufacturer's recommendations, the addition of between 30 to 120 parts of water per 100 parts of prepolymer resin.
  • the catalyst system may also include between 0.5 and 2.0 grams of cell modifier such as polydimethylsiloxane or the equivalent per 100 grams of prepolymer resin.
  • the polymeric mass can also be prepared directly from prepolymer precursors and catalysts by employing the procedure generally known in the art as the "one step” method and incorporating therein the proprietary techniques used during the final stages of the mixing procedure.
  • the range of medicaments which may be dispersed within the polyurethane body of foam in the foregoing manner is quite extensive and depends upon the particular use intended.
  • the additives may be particulate solids, ointments or miscible and immiscible liquids. Active ingredients such as bactericides, germicides, and antibiotics can be used for the treatment of abnormal vaginal conditions such as moniliasis, trichomonasis and other non-specific types of vaginitis. Other formulations are also possible for use by physicians to "prep" patients prior to vaginal, cervical or peri-anal surgery. Soaps, detergents, emollients, fragrances and even colors can be used to prepare applicators for use in general feminine hygiene. In many instances these additives would also be included in foam applicators for specific purposes as inert carriers of the active compound. Table I lists and identifies commercially available medicaments and additives which may be incorporated into the foam in recommended dosages.
  • Dry additives and additives in ointment form which are to be dispersed within the polymeric mass are preferably premixed to obtain a uniform composition. Because liquid medicaments are easily dispersed within the polymeric mass, they may be either premixed with the dry additives or introduced directly into the polymeric mass at any time during the second or subsequent mixing steps, but at least 15 seconds prior to the termination of mixing to ensure complete and uniform dispersion.
  • the second mixing step which is performed at 250 to 1000 RPM for 15 to 100 seconds, preferably at 400 to 700 RPM for 30 to 80 seconds, not only serves to disperse the additives within the polymeric mass to obtain a uniform reacting mixture, but also regulates cell formation.
  • the agitation disperses evolved gases which are necessary for foaming of the polymeric reactants. Hence, active foaming is minimized.
  • the agitation produces shear forces that tear or shred a portion of the cells formed during this step.
  • the finished applicator head when observed under a microscope, contains fibrous threads of polymerized polyurethane interwoven throughout the cellular matrix.
  • the shear forces of the second mixing step also create large numbers of distorted, collapsed and stretched cells. Many of these cells, even those forming the skin of the final applicator head, are hydrophilic in nature, and allow water to enter and to dissolve the medicaments contained therein. Thus, the foam applicators do not require a highly reticulated surface for the release of the additives.
  • the twice-mixed polymeric mass i.e. the uniform reacting mixture
  • the foam applicator is made by pouring the uniform reacting mixture obtained by the foregoing procedure into a closed two-cavity mold containing the desired supporting structure.
  • the mold is desirably constructed of two mating sections operating laterally against each other to allow the reacting mixture to be poured in and to release the finished applicator assembly.
  • the polymeric mix is sufficiently fluid to conform exactly to the shape of the cavities as it begins to foam.
  • the foaming material can also penetrate holes and surround intricate surface discontinuities thereby forming an integral bond between foam and support. While the foaming material is densified by expanding in a close mold, the finished body of foam is soft, pliable and can readily absorb and release water or body fluids.
  • Encapsulation can be achieved by two methods. In the first method, a previously prepared body of foam containing additives is shredded or comminuted to between 20 to 100 U.S. Standard Sieve and then blended into the partially reacted mass during the second mixing stage. Although all of the additives may be encapsulated by this method, it is most useful where only a liquid additive, typically an emollient, is to be coated, or where a mixture of emollient and dry additives could not be encapsulated effectively in any other way.
  • a liquid additive typically an emollient
  • the second method encapsulates the additives, either individually or in combination with one another with a water soluble film using a film forming material such as polyvinyl alcohol, polyvinyl pyrrolidone, hydroxymethyl cellulose, polyvinyl methylether, polyacrylamide or Triton X-100.
  • a film forming material such as polyvinyl alcohol, polyvinyl pyrrolidone, hydroxymethyl cellulose, polyvinyl methylether, polyacrylamide or Triton X-100.
  • An atomized mist of a 1 to 5 percent aqueous solution of the film former is sprayed onto the additive (s), and the moisture is allowed to evaporate therefrom. This operation may be carried out in a tumble dryer or fluidized bed dryer with warm air used for drying.
  • the treated additives are then comminuted to between 60 and 100 mesh and added to the partially reacted mass in the second mixing step.
  • the second method is preferred for dry additive mixtures that do not tend to clump or agglomerate.
  • glycol bases of the shell or sheath can be varied in composition.
  • a lower melting point is accomplished by decreasing the amount of higher molecular weight glycols whereas, to achieve higher melting points, the amount of higher molecular weight glycols is increased.
  • the proportions for incorporating water and medications to the glycol base are as follows:
  • Theobroma oil (cocoa butter) can be used as a carrier of medications for the shell and sheath. This can be prepared by melting the Theobroma oil and by intimately incorporating into it an equal amount of medicaments by weight. The rest of the required amount of Theobroma oil is then admixed to the melted liquid. The ingredients are then cooled down to almost the desired melting point, uniformly mixed and poured into chilled cavities to cast either a shell or sheath. The melting range of Theobroma oil of 30 to 35°C can be increased by the addition of white wax.
  • Other carriers may be polyethylene derivative of sorbitan monostearate (Tween 61 by Atlas Chemical), polyoxyethylene 30 stearate (Myrj 51 by Atlas Chemical) or polyoxyl 40 stearate (Myrj 52 by Atlas Chemical).
  • either the shell or the sheath structure can be composed of several heat-meltable layers of the same medications in addition to the pre-medicated body of foam.
  • Such arrangement guarantees a prolonged medicinal action particularly useful for therapeutic tampons.
  • a fresh layer of medications can be dissolved for absorption approximately every hour or so.
  • the present technology also allows for the production of therapeutic tampons incorporating two different medications to be applied in sequence which is sometimes required for certain specific vaginal disorders.
  • a tampon could comprise a partial outer layer of quickly dissolving cocoa butter to facilitate passage and insertion in the vaginal tract. This outer layer could be followed by two or more full-length inner layers of medications. Once the shell layers are fully dissolved, a different medication pre-impregnated in the foam could come into effect activated by either body heat and/or body secretions.
  • a surgical swab-stick such as shown in Figures 5-16 or an iodine douching swab or sleeve such as shown in Figures 21-29 for patient prepping or for therapeutic douching for vaginitis is prepared from the following formulation:
  • the tegostab is first added to the resin followed by the water. These ingredients are mixed until foam begins to rise or begins to expand. At this point, the povidone-iodine powder is added and the mixture is stir-mixed for three to five seconds before being poured into a mold. For topical use, the povidone-iodine powder may be adjusted to .075 to 1 percent of available iodine. EXAMPLE III.
  • a vaginal cleanser such as shown in Figures 5-14 or a douching sleeve (without a shell) such as shown in Figures 26-29 is formulated as follows: Formula A Swab Douching Sleeve Hypol 2001 6.0 gm 6.0 gm H 2 0 Purified 6.0 ml 6.0 ml Tegostab 2270 0.6 gm 0.6 gm
  • the glycols are first blended on a water bath until liquid and clear.
  • the citrate and bicarbonate are then added and stirred into the glycols until solidified.
  • This solidified mass is chilled and granulated to about 40 to 100 mesh.
  • the prepolymer F 202, catalyst and sodium lauryl sulfate are rapidly mixed. When foaming begins, the granulated mix is added, stirred for about three to ten seconds, and poured into molds.
  • the preferred catalyst for this formulation is comprised of H 2 0 66.6 percent; triethanolamine 20.8 percent; triethylenediamine 12.6 percent.
  • a medicated shell for an antifungal tampon illustrated in Figure 19 for the treatment of vaginitis is prepared using the following formulation:
  • a medicated therapeutic tampon including a shell such as shown in Figure 19 for the treatment of trichomonas vaginalis, monilia (candida albicans) and haemophilus vaginalis is produced utilizing three separate formulations: One for the shell and two for the tampon per se.
  • Nifuroxime 0.4125 gm
  • the polyethylene glycols and the stearyl alcohol are heated to about 65°C and stirred.
  • the furazolidone and nifuroxime are subsequently added, thoroughly mixed and poured into a shell mold and chilled.
  • the polyethylene glycol and stearyl alcohol are heated in a water bath to about 65°C and mixed. After blending, the remaining ingredients are added and thoroughly mixed. The resulting mixture is then cooled and chilled until solid. This solid mass is granulated to a range of 40 to 100 mesh.
  • Tampon Formula (Column 5 ingredients, single unit)
  • the tegostab is first added to the resin and then combined with the water. These are rapidly mixed until foaming has started at which time 2.7 gms of the granulated mix from Formula B above is added. This is stirred rapidly and poured into a mold.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)

Abstract

Des applicateurs locaux de nature cellulaire poreuse (12) sont essentiellement concus pour etre utilises sur les muqueuses des cavites du corps humain ou animal tel que l'appareil vaginal. L'invention s'applique particulierement a des dispositifs de faible cout, de volume et de masse reduits, jetables, preimpregnes avec des compositions therapeutiques seches, liquides ou semi-liquides (102).
PCT/US1980/001030 1979-08-13 1980-08-13 Applicateurs de polymeres medicamenteux WO1981000356A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU63328/80A AU6332880A (en) 1979-08-13 1980-08-13 Polymeric drug delivery applicators
BR8008784A BR8008784A (pt) 1979-08-13 1980-08-13 Aplicadores para suprimento de drogas polimera

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6588379A 1979-08-13 1979-08-13
US65883 1979-08-13

Publications (1)

Publication Number Publication Date
WO1981000356A1 true WO1981000356A1 (fr) 1981-02-19

Family

ID=22065786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1980/001030 WO1981000356A1 (fr) 1979-08-13 1980-08-13 Applicateurs de polymeres medicamenteux

Country Status (7)

Country Link
EP (1) EP0035531A4 (fr)
JP (1) JPS56501154A (fr)
BR (1) BR8008784A (fr)
CA (1) CA1158512A (fr)
NZ (1) NZ194468A (fr)
WO (1) WO1981000356A1 (fr)
ZA (1) ZA804846B (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0082894A1 (fr) * 1981-12-30 1983-07-06 The Population Council, Inc. Procédé pour la fabrication de dispositifs intra-utérins
WO1996031250A1 (fr) * 1995-04-06 1996-10-10 Richwood Pharmaceuticals Company, Inc. Systeme de perfusion pour l'administration de medicaments dans une cavite du corps
ES2115509A1 (es) * 1995-11-28 1998-06-16 Raga Manuel Martinez Dispositivo para la higiene vaginal.
WO1999040966A1 (fr) * 1998-02-13 1999-08-19 Graham Francois Duirs Dispositif servant a administrer un medicament
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
WO2005063162A1 (fr) * 2003-11-21 2005-07-14 The Procter & Gamble Company Tampon
GB2429157A (en) * 2005-08-17 2007-02-21 Mike Coventry Nostril cleaning swab
US7431717B2 (en) 2003-09-30 2008-10-07 Serene Medical, Inc. Central nervous system administration of medications by means of pelvic venous catheterization and reversal of Batson's Plexus
DE102008061536A1 (de) * 2008-12-03 2010-06-10 Aesculap Ag Medizintechnischer Saugkörper, insbesondere zur Entfernung von Wundflüssigkeiten aus menschlichen und/oder tierischen Körperhöhlen
EP2786713A1 (fr) * 2011-11-30 2014-10-08 Olympus Medical Systems Corp. Dispositif médical
EP2641545A4 (fr) * 2010-11-12 2017-12-13 Nipro Corporation Écouvillon
WO2020008245A1 (fr) * 2018-07-06 2020-01-09 Polymed S.R.L. Dispositif d'administration intravaginale de substances
CN116808415A (zh) * 2023-08-28 2023-09-29 四川省医学科学院·四川省人民医院 一种腔道供药装置

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6831533B2 (ja) * 2016-12-05 2021-02-17 国立大学法人大阪大学 医療用綿棒

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3343540A (en) * 1964-04-27 1967-09-26 Frederick P Siegel Swab-type applicator with impregnated medicament
US3389418A (en) * 1965-10-01 1968-06-25 Dwight M. Sencabaugh Applicator and massage device
US3813462A (en) * 1965-05-14 1974-05-28 A Roberts Process for the manufacture of molded articles
US3818911A (en) * 1972-05-11 1974-06-25 E Fournier Medicament and swab type applicators
JPS4966762A (fr) * 1972-08-26 1974-06-28
US3985951A (en) * 1975-07-10 1976-10-12 Niemand Bros. Inc. Electrical insulator including a polymeric resin foam forming composition and method of insulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3343540A (en) * 1964-04-27 1967-09-26 Frederick P Siegel Swab-type applicator with impregnated medicament
US3813462A (en) * 1965-05-14 1974-05-28 A Roberts Process for the manufacture of molded articles
US3389418A (en) * 1965-10-01 1968-06-25 Dwight M. Sencabaugh Applicator and massage device
US3818911A (en) * 1972-05-11 1974-06-25 E Fournier Medicament and swab type applicators
JPS4966762A (fr) * 1972-08-26 1974-06-28
US3985951A (en) * 1975-07-10 1976-10-12 Niemand Bros. Inc. Electrical insulator including a polymeric resin foam forming composition and method of insulation

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0082894A1 (fr) * 1981-12-30 1983-07-06 The Population Council, Inc. Procédé pour la fabrication de dispositifs intra-utérins
WO1996031250A1 (fr) * 1995-04-06 1996-10-10 Richwood Pharmaceuticals Company, Inc. Systeme de perfusion pour l'administration de medicaments dans une cavite du corps
GB2314777A (en) * 1995-04-06 1998-01-14 Richwood Pharmaceuticals Compa Infusor system for delivery of medication to a body cavity
US5830186A (en) * 1995-04-06 1998-11-03 G. & P. Technologies, Inc. Method of dispensing medications by use of mucous membrane infusor
US5846216A (en) * 1995-04-06 1998-12-08 G & P Technologies, Inc. Mucous membrane infusor and method of use for dispensing medications
GB2314777B (en) * 1995-04-06 1999-04-28 Richwood Pharmaceuticals Compa Mucous membrane infusor
ES2115509A1 (es) * 1995-11-28 1998-06-16 Raga Manuel Martinez Dispositivo para la higiene vaginal.
US6770288B2 (en) 1998-02-13 2004-08-03 Pfizer Products Inc. Drug delivery system
WO1999040966A1 (fr) * 1998-02-13 1999-08-19 Graham Francois Duirs Dispositif servant a administrer un medicament
AU741072B2 (en) * 1998-02-13 2001-11-22 Vetoquinol Usa, Inc. Drug delivery system
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
US7431717B2 (en) 2003-09-30 2008-10-07 Serene Medical, Inc. Central nervous system administration of medications by means of pelvic venous catheterization and reversal of Batson's Plexus
WO2005063162A1 (fr) * 2003-11-21 2005-07-14 The Procter & Gamble Company Tampon
US7338483B2 (en) 2003-11-21 2008-03-04 The Procter & Gamble Company Tampon
GB2429157A (en) * 2005-08-17 2007-02-21 Mike Coventry Nostril cleaning swab
DE102008061536A1 (de) * 2008-12-03 2010-06-10 Aesculap Ag Medizintechnischer Saugkörper, insbesondere zur Entfernung von Wundflüssigkeiten aus menschlichen und/oder tierischen Körperhöhlen
EP2641545A4 (fr) * 2010-11-12 2017-12-13 Nipro Corporation Écouvillon
EP2786713A1 (fr) * 2011-11-30 2014-10-08 Olympus Medical Systems Corp. Dispositif médical
EP2786713A4 (fr) * 2011-11-30 2015-11-11 Olympus Corp Dispositif médical
WO2020008245A1 (fr) * 2018-07-06 2020-01-09 Polymed S.R.L. Dispositif d'administration intravaginale de substances
CN116808415A (zh) * 2023-08-28 2023-09-29 四川省医学科学院·四川省人民医院 一种腔道供药装置
CN116808415B (zh) * 2023-08-28 2023-11-07 四川省医学科学院·四川省人民医院 一种腔道供药装置

Also Published As

Publication number Publication date
BR8008784A (pt) 1981-06-09
CA1158512A (fr) 1983-12-13
NZ194468A (en) 1982-11-23
ZA804846B (en) 1981-08-26
EP0035531A4 (fr) 1981-12-10
JPS56501154A (fr) 1981-08-20
EP0035531A1 (fr) 1981-09-16

Similar Documents

Publication Publication Date Title
CA1158512A (fr) Applicateur polymerique impregne de medicament
US6264638B1 (en) Intravaginal drug delivery system and discharge collection device
EP0016159B1 (fr) Barriere cervicale contraceptive jetable
US4311543A (en) Method of manufacturing a disposable contraceptive intravaginal cervical barrier
EP1861057B1 (fr) Assemblage formant un tube destine a un applicateur
US8388996B2 (en) Methods of manufacturing a medicated tampon assembly
DE60106365T2 (de) Medikamentenabgabevorrichtung zum Einsetzen in die Vagina, das Rektum oder die Nasenhöhle
US3424158A (en) Combination plastic mold,suppository package,dispenser and method for providing and using the same
US7527614B2 (en) Protective tube for a medicated tampon
JP2008535558A (ja) 潤滑性を付与したタンポンアプリケータ
DE3634864A1 (de) Abgabevorrichtung zur freisetzung einer auf temperatur ansprechenden masse
JP2008534171A (ja) 新規なタンポンアプリケータ
DE3509743C2 (de) Abgabevorrichtung zur Freisetzung eines Wirkstoffs
EP1861056A1 (fr) Assemblage formant un embout de dosage destine a un applicateur
IE55990B1 (en) Programmed release device and method of use thereof
US20070128254A1 (en) Methods of attaching a dosage form to a medicated tampon assembly
AU6332880A (en) Polymeric drug delivery applicators
Shitut et al. Rectal and Vaginal Routes of Drug Delivery
WO1998043687A1 (fr) Dispositif collecteur de pertes et systeme d'administration intravaginale de medicament

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU BR DK JP NO

AL Designated countries for regional patents

Designated state(s): AT CH DE FR GB LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1980901748

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1980901748

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1980901748

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1980901748

Country of ref document: EP